{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:15:48Z","timestamp":1790882148177,"version":"4.1.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Norman Bethune Program of Jilin University","award":["2022B17"],"award-info":[{"award-number":["2022B17"]}]},{"name":"Talent Reserve Program (TRP), the First Hospital of Jilin University","award":["JDYYCB-2023007"],"award-info":[{"award-number":["JDYYCB-2023007"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec017\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>Hematological malignancies (HMs) pose a severe threat to human health and contribute substantially to the disease burden in mainland China and Taiwan. Therefore, understanding their burden is crucial for informed decision-making and the effective allocation of healthcare resources.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec018\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This study utilized the latest data from the Global Burden of Disease 2021 study to describe the epidemiological indices of HMs in mainland China and Taiwan from 1990 to 2021. The future disease burden was projected for the next decade using the Bayesian age-period cohort (BAPC) model.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec019\">\n<jats:title>Results<\/jats:title>\n<jats:p>Between 1990 and 2021, mainland China experienced an increase in the prevalence and incidence of leukemia and lymphoma, while the mortality and disability-adjusted life years (DALYs) for these diseases declined. Conversely, Taiwan witnessed an overall increase in the prevalence, incidence, mortality, and DALYs of leukemia over the same period. Additionally, multiple myeloma (MM), myelodysplastic\/myeloproliferative neoplasms, and other hematopoietic neoplasms have shown significant increases in prevalence, incidence, mortality, and DALYs in China. While the disease burden of myeloid leukemia decreased in mainland China, that of lymphoid neoplasms (including leukemia, lymphoma, and MM) increased, which was not observed in Taiwan. Predictions from the BAPC model suggest that the incidence of several lymphoid neoplasms and MM is expected to increase in mainland China and Taiwan.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec020\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Taiwan continues to face greater challenges in managing HMs compared to mainland China. MM imposes a significant burden on the Chinese population. The findings of this study provide valuable epidemiological insights for optimizing the allocation of medical resources.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0328526","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T17:26:42Z","timestamp":1753118802000},"page":"e0328526","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hematological malignancy burden in mainland China and Taiwan from 1990 to 2021 and decadal projections: Insights from the global burden of disease study 2021"],"prefix":"10.1371","volume":"20","author":[{"given":"Yu","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Zhe","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5360-468X","authenticated-orcid":true,"given":"Long","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"29","key":"pone.0328526.ref001","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.23.02238","article-title":"Genomic determinants of outcome in acute lymphoblastic leukemia","volume":"42","author":"TC Chang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0328526.ref002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"E Jabbour","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"3","key":"pone.0328526.ref003","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"S Shimony","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"pone.0328526.ref004","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","article-title":"Contemporary management of acute myeloid leukemia: a review","volume":"10","author":"S Venugopal","year":"2024","journal-title":"JAMA Oncol"},{"issue":"11","key":"pone.0328526.ref005","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"M Shadman","year":"2023","journal-title":"JAMA"},{"issue":"10453","key":"pone.0328526.ref006","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0140-6736(24)00595-6","article-title":"Chronic lymphocytic leukaemia","volume":"404","author":"N Jain","year":"2024","journal-title":"Lancet"},{"issue":"23","key":"pone.0328526.ref007","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/cncr.35038","article-title":"Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy - the surveillance, epidemiology, and end results database, 2000-2019","volume":"129","author":"K Sasaki","year":"2023","journal-title":"Cancer"},{"issue":"10","key":"pone.0328526.ref008","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"A Hochhaus","year":"2024","journal-title":"New Engl J Med"},{"key":"pone.0328526.ref009","doi-asserted-by":"crossref","first-page":"101196","DOI":"10.1016\/j.blre.2024.101196","article-title":"Chronic myeloid leukaemia: biology and therapy","volume":"65","author":"Y Wang","year":"2024","journal-title":"Blood Rev"},{"issue":"6","key":"pone.0328526.ref010","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3239","article-title":"Classic Hodgkin lymphoma","volume":"42","author":"J Kahn","year":"2024","journal-title":"Hematological oncology"},{"issue":"3","key":"pone.0328526.ref011","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ajh.27202","article-title":"The lymphoma epidemiology of outcomes cohort study: design, baseline characteristics, and early outcomes","volume":"99","author":"JR Cerhan","year":"2024","journal-title":"Am J Hematol"},{"issue":"9","key":"pone.0328526.ref012","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"LH Sehn","year":"2021","journal-title":"New Engl J Med"},{"issue":"1","key":"pone.0328526.ref013","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"A Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"pone.0328526.ref014","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-024-00989-w","article-title":"Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives","volume":"14","author":"I Abou Dalle","year":"2024","journal-title":"Blood Cancer J"},{"issue":"10343","key":"pone.0328526.ref015","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"M Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"pone.0328526.ref016","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"SV Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"24","key":"pone.0328526.ref017","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"A Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0328526.ref018","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"H Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"pone.0328526.ref019","first-page":"324","article-title":"NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia","volume":"19","author":"L Su","year":"2014","journal-title":"Hematology (Amsterdam, Netherlands)"},{"key":"pone.0328526.ref020","doi-asserted-by":"crossref","first-page":"806137","DOI":"10.3389\/fonc.2022.806137","article-title":"Acute myeloid leukemia with CEBPA mutations: current progress and future directions","volume":"12","author":"L Su","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"pone.0328526.ref021","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40364-024-00649-y","article-title":"Global, regional, and national burden of acute myeloid leukemia, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"12","author":"Y Zhou","year":"2024","journal-title":"Biomarker Res"},{"issue":"1","key":"pone.0328526.ref022","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41408-024-01138-z","article-title":"Global, regional, and national burden of Burkitt lymphoma from 1990 to 2021 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2021","volume":"14","author":"Y Wang","year":"2024","journal-title":"Blood Cancer J"},{"key":"pone.0328526.ref023","doi-asserted-by":"crossref","first-page":"1425043","DOI":"10.3389\/fpubh.2024.1425043","article-title":"Comparison of secular trends of leukemia in China and the United States from 1990 to 2021 and their projections for the next 15 years","volume":"12","author":"X Ge","year":"2024","journal-title":"Front Public Health"},{"key":"pone.0328526.ref024","doi-asserted-by":"crossref","first-page":"102619","DOI":"10.1016\/j.eclinm.2024.102619","article-title":"Global, regional, and national burden of thalassemia, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"72","author":"Y Tuo","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"3","key":"pone.0328526.ref025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019","volume":"13","author":"R Wang","year":"2023","journal-title":"BMJ Open"},{"issue":"6","key":"pone.0328526.ref026","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1159\/000511205","article-title":"Joinpoint regression analysis of trends in multiple sclerosis incidence in Kuwait: 1980-2019","volume":"54","author":"S Akhtar","year":"2020","journal-title":"Neuroepidemiology"},{"issue":"1","key":"pone.0328526.ref027","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10194-024-01798-z","article-title":"Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the Global Burden of Disease Study 2021","volume":"25","author":"J Cen","year":"2024","journal-title":"J Headache Pain"},{"issue":"2","key":"pone.0328526.ref028","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/03014460.2019.1707872","article-title":"Age period cohort analysis: a review of what we should and shouldn\u2019t do","volume":"47","author":"A Bell","year":"2020","journal-title":"Ann Hum Biol"},{"issue":"3","key":"pone.0328526.ref029","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/0049124119882451","article-title":"The age-period-cohort-interaction model for describing and investigating inter-cohort deviations and intra-cohort life-course dynamics","volume":"51","author":"L Luo","year":"2022","journal-title":"Sociol Methods Res"},{"issue":"8","key":"pone.0328526.ref030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/1759-7714.15227","article-title":"Global, regional, and national burden and trends of early-onset tracheal, bronchus, and lung cancer from 1990 to 2019","volume":"15","author":"J Ma","year":"2024","journal-title":"Thorac Cancer"},{"issue":"1","key":"pone.0328526.ref031","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"N Zhang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"18","key":"pone.0328526.ref032","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70224","article-title":"Trend analysis of hematological tumors in adolescents and young adults from 1990 to 2019 and predictive trends from 2020 to 2044: a Global Burden of Disease study","volume":"13","author":"L Huang","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"pone.0328526.ref033","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"B Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"issue":"6","key":"pone.0328526.ref034","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jfma.2022.10.007","article-title":"Epidemiology and survival outcomes of acute myeloid leukemia patients in Taiwan: A national population-based analysis from 2001 to 2015","volume":"122","author":"L-N Chien","year":"2023","journal-title":"J Formos Med Assoc"},{"issue":"8","key":"pone.0328526.ref035","article-title":"Epidemiology, treatment patterns and survival of chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL) in Taiwan, 2006-2015","volume":"75","author":"B-S Ko","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"9","key":"pone.0328526.ref036","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"J Huang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"pone.0328526.ref037","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1002\/cam4.1622","article-title":"Rituximab maintenance improves overall survival in follicular lymphoma: a retrospective nationwide real-world analysis from Taiwan Cancer Registry Database","volume":"7","author":"H-H Huang","year":"2018","journal-title":"Cancer Med"},{"key":"pone.0328526.ref038","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1186\/s12885-016-2523-7","article-title":"Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study","volume":"16","author":"J Wu","year":"2016","journal-title":"BMC Cancer"},{"issue":"6","key":"pone.0328526.ref039","first-page":"281","article-title":"Treatment of 54 chronic myelogenous leukemia with Gleevec","volume":"24","author":"H Jiang","year":"2003","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"pone.0328526.ref040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12185-008-0230-0","article-title":"Chronic myeloid leukemia in Asia","volume":"89","author":"WY Au","year":"2009","journal-title":"Int J Hematol"},{"issue":"13","key":"pone.0328526.ref041","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1021\/acs.est.3c10159","article-title":"The global environmental impacts of China\u2019s accession to the WTO: a 20-year review","volume":"58","author":"J Lu","year":"2024","journal-title":"Environ Sci Technol"},{"key":"pone.0328526.ref042","doi-asserted-by":"crossref","first-page":"798686","DOI":"10.3389\/fpubh.2022.798686","article-title":"Export expansion may increase adult illness and injury: a quasi-natural experiment on China\u2019s accession to the World Trade Organization","volume":"10","author":"H Chen","year":"2022","journal-title":"Front Public Health"},{"issue":"2","key":"pone.0328526.ref043","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/tc.2006.018374","article-title":"British American Tobacco\u2019s tactics during China\u2019s accession to the World Trade Organization","volume":"16","author":"F Zhong","year":"2007","journal-title":"Tob Control"},{"issue":"3","key":"pone.0328526.ref044","first-page":"367","article-title":"Lifestyle factors and risk of leukemia and non-Hodgkin\u2019s lymphoma: a case-control study","volume":"27","author":"S Parodi","year":"2016","journal-title":"Cancer Causes Control"},{"key":"pone.0328526.ref045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cbi.2015.06.009","article-title":"A comprehensive review of occupational and general population cancer risk: 1,3-Butadiene exposure-response modeling for all leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloid neoplasm and lymphoid neoplasm","volume":"241","author":"RL Sielken","year":"2015","journal-title":"Chem Biol Interact"},{"issue":"5","key":"pone.0328526.ref046","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/joim.12684","article-title":"The aetiology of B-cell lymphoid malignancies with a focus on chronic inflammation and infections","volume":"282","author":"KE Smedby","year":"2017","journal-title":"J Intern Med"},{"issue":"10272","key":"pone.0328526.ref047","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"NWCJ van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"pone.0328526.ref048","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41423-020-00597-1","article-title":"Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation","volume":"18","author":"H Guo","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"pone.0328526.ref049","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/CM9.0000000000001852","article-title":"Haploidentical transplantation has a superior graft-versus-leukemia effect than HLA-matched sibling transplantation for Ph- high-risk B-cell acute lymphoblastic leukemia","volume":"135","author":"M Fan","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"20","key":"pone.0328526.ref050","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial","volume":"121","author":"H-H Zhu","year":"2013","journal-title":"Blood"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T17:26:51Z","timestamp":1753118811000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328526"}},"subtitle":[],"editor":[{"given":"Mehmet","family":"Baysal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0328526","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}